Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sera PrognosticsSERA +2.90%70 Debt-to-Equity is 0.04 as of Mar. 2026, which is 100% above its 10-year median of 0.02. GuruFocus rates SERA with a GF Score™ of 70/100 and a GF Value™ of $1.82 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Sera Prognostics ranks better than 85.53% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sera Prognostics's Debt-to-Equity or its related term are showing as below:
SERA'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.09 Med: 0.02 Max: 0.04
Current: 0.04
During the past 7 years, the highest Debt-to-Equity Ratio of Sera Prognostics was 0.04. The lowest was -0.09. And the median was 0.02.
SERA's Debt-to-Equity is ranked better than 85.53% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs SERA: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sera Prognostics Debt-to-Equity Related Terms
Sera Prognostics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Sera Prognostics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SERA vs ZOMDF, OM, LNSR: Debt-to-Equity Comparison
For the Medical Devices subindustry, Sera Prognostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sera Prognostics Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sera Prognostics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sera Prognostics (SERA) has a Debt-to-Equity of 0.04 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sera Prognostics and its competitors. This is 100% above median its historical median of 0.02. According to the industry distribution chart, Sera Prognostics ranks #102 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 14.5%.
Is Sera Prognostics' Debt-to-Equity too high?
Sera Prognostics' current Debt-to-Equity of 0.04 is 100% above median its 10-year median of 0.02. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Sera Prognostics' value of 0.04 is 82.6% below this industry median. Based on the distribution chart, Sera Prognostics ranks #102 out of 705 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sera Prognostics has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' Debt-to-Equity compare to ZOMDF and OM?
According to the Medical Devices & Instruments industry distribution chart, Sera Prognostics ranks #102 out of 705 companies for Debt-to-Equity. This places Sera Prognostics in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Sera Prognostics' value of 0.04 is 82.6% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.23, Sera Prognostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sera Prognostics's current Debt-to-Equity of 0.04 is 82.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sera Prognostics and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sera Prognostics's current Debt-to-Equity is 0.04, which is 100% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.82, compared to a current price of $2.13 — trading 17% above its estimated fair value. The current Debt-to-Equity is 0.04, which is 100% above median its 10-year median of 0.02 and 82.6% below the Medical Devices & Instruments industry median of 0.23. Sera Prognostics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sera Prognostics (SERA), the current Debt-to-Equity is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sera Prognostics (SERA) Overvalued in 2026?
Based on GuruFocus' analysis, Sera Prognostics stock appears to be overvalued.
The current stock price of $2.13 is trading 17% above its estimated GF Value™ of $1.82.
GuruFocus considers Sera Prognostics to be Modestly Overvalued.
Key valuation signals for SERA:
Debt-to-Equity: 0.04 (100% above median its 10-year median of 0.02)
GF Value™: $1.82 vs. price of $2.13 (17% above fair value)
Industry Position: 82.6% below the Medical Devices & Instruments median (#102 of 705)
No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
70GF Score
Get the complete analysis for SERA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SERA has been successfully added to your 
